1 Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A Consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–61.
2 Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: Data from the French Acromegaly Registry. Eur J Endocrinol. 2011;164(6):877–84.
3 Yoshida N, Goto H, Suzuki H, Nagasawa K, Takeshita A, Okubo M, et al. Ketoacidosis as the initial clinical condition in nine patients with acromegaly: A review of 860 cases at a single institute. Eur J Endocrinol. 2013;169(1):127–32.
4 Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008;29(3):292–302.
5 Vijayakumar A, Yakar S, Leroith D. The intricate role of growth hormone in metabolism. Front Endocrinol (Lausanne). 2011;2:32.
6 Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin EndocrinolMetab. 2014;99(11):3933–51.